BEAMing sheds light on drug resistance.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 22065078.
- Also identified by DOI 10.1158/1078-0432.CCR-11-2556 and PMC identifier 3243814.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Targeted therapies against somatically altered genes are currently used for the treatment of many human cancers. The nascent technology known as BEAMing has the potential to increase the clinical utility of these agents because it allows for the detection of cancer mutations in peripheral blood, providing a rapid assessment of tumor mutation status.
Medical subject headings
- Adenocarcinoma
- DNA Mutational Analysis
- DNA, Neoplasm
- ErbB Receptors
- Lung Neoplasms
- Mutation